Cargando…

Drug Repurposing: A New Hope in Drug Discovery for Prostate Cancer

[Image: see text] Prostate cancer (PCA), the most common cancer in men, accounted for 1.3 million new incidences in 2018. An increase in incidences is an issue of concern that should be addressed. Of all the reported prostate cancers, 85% were detected in stages III and IV, making them difficult to...

Descripción completa

Detalles Bibliográficos
Autores principales: Malik, Jonaid Ahmad, Ahmed, Sakeel, Momin, Sadiya Sikandar, Shaikh, Sijal, Alafnan, Ahmed, Alanazi, Jowaher, Said Almermesh, Mohammad Hajaj, Anwar, Sirajudheen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835086/
https://www.ncbi.nlm.nih.gov/pubmed/36643505
http://dx.doi.org/10.1021/acsomega.2c05821
_version_ 1784868599910891520
author Malik, Jonaid Ahmad
Ahmed, Sakeel
Momin, Sadiya Sikandar
Shaikh, Sijal
Alafnan, Ahmed
Alanazi, Jowaher
Said Almermesh, Mohammad Hajaj
Anwar, Sirajudheen
author_facet Malik, Jonaid Ahmad
Ahmed, Sakeel
Momin, Sadiya Sikandar
Shaikh, Sijal
Alafnan, Ahmed
Alanazi, Jowaher
Said Almermesh, Mohammad Hajaj
Anwar, Sirajudheen
author_sort Malik, Jonaid Ahmad
collection PubMed
description [Image: see text] Prostate cancer (PCA), the most common cancer in men, accounted for 1.3 million new incidences in 2018. An increase in incidences is an issue of concern that should be addressed. Of all the reported prostate cancers, 85% were detected in stages III and IV, making them difficult to treat. Conventional drugs gradually lose their efficacy due to the developed resistance against them, thus requiring newer therapeutic agents to be used as monotherapy or combination. Recent research regarding treatment options has attained remarkable speed and development. Therefore, in this context, drug repurposing comes into the picture, which is defined as the “investigation of the off-patent, approved and marketed drugs for a novel therapeutic indication” which saves at least 30% of the time and cost, reducing the cost of treatment for patients, which usually runs high in cancer patients. The anticancer property of cardiac glycosides in cancers was tested in the early 1980s. The trend then shifts toward treating prostate cancer by repurposing other cardiovascular drugs. The current review mainly emphasizes the advantageous antiprostate cancer profile of conventional CVS drugs like cardiac glycosides, RAAS inhibitors, statins, heparin, and beta-blockers with underlying mechanisms.
format Online
Article
Text
id pubmed-9835086
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-98350862023-01-13 Drug Repurposing: A New Hope in Drug Discovery for Prostate Cancer Malik, Jonaid Ahmad Ahmed, Sakeel Momin, Sadiya Sikandar Shaikh, Sijal Alafnan, Ahmed Alanazi, Jowaher Said Almermesh, Mohammad Hajaj Anwar, Sirajudheen ACS Omega [Image: see text] Prostate cancer (PCA), the most common cancer in men, accounted for 1.3 million new incidences in 2018. An increase in incidences is an issue of concern that should be addressed. Of all the reported prostate cancers, 85% were detected in stages III and IV, making them difficult to treat. Conventional drugs gradually lose their efficacy due to the developed resistance against them, thus requiring newer therapeutic agents to be used as monotherapy or combination. Recent research regarding treatment options has attained remarkable speed and development. Therefore, in this context, drug repurposing comes into the picture, which is defined as the “investigation of the off-patent, approved and marketed drugs for a novel therapeutic indication” which saves at least 30% of the time and cost, reducing the cost of treatment for patients, which usually runs high in cancer patients. The anticancer property of cardiac glycosides in cancers was tested in the early 1980s. The trend then shifts toward treating prostate cancer by repurposing other cardiovascular drugs. The current review mainly emphasizes the advantageous antiprostate cancer profile of conventional CVS drugs like cardiac glycosides, RAAS inhibitors, statins, heparin, and beta-blockers with underlying mechanisms. American Chemical Society 2022-12-29 /pmc/articles/PMC9835086/ /pubmed/36643505 http://dx.doi.org/10.1021/acsomega.2c05821 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Malik, Jonaid Ahmad
Ahmed, Sakeel
Momin, Sadiya Sikandar
Shaikh, Sijal
Alafnan, Ahmed
Alanazi, Jowaher
Said Almermesh, Mohammad Hajaj
Anwar, Sirajudheen
Drug Repurposing: A New Hope in Drug Discovery for Prostate Cancer
title Drug Repurposing: A New Hope in Drug Discovery for Prostate Cancer
title_full Drug Repurposing: A New Hope in Drug Discovery for Prostate Cancer
title_fullStr Drug Repurposing: A New Hope in Drug Discovery for Prostate Cancer
title_full_unstemmed Drug Repurposing: A New Hope in Drug Discovery for Prostate Cancer
title_short Drug Repurposing: A New Hope in Drug Discovery for Prostate Cancer
title_sort drug repurposing: a new hope in drug discovery for prostate cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835086/
https://www.ncbi.nlm.nih.gov/pubmed/36643505
http://dx.doi.org/10.1021/acsomega.2c05821
work_keys_str_mv AT malikjonaidahmad drugrepurposinganewhopeindrugdiscoveryforprostatecancer
AT ahmedsakeel drugrepurposinganewhopeindrugdiscoveryforprostatecancer
AT mominsadiyasikandar drugrepurposinganewhopeindrugdiscoveryforprostatecancer
AT shaikhsijal drugrepurposinganewhopeindrugdiscoveryforprostatecancer
AT alafnanahmed drugrepurposinganewhopeindrugdiscoveryforprostatecancer
AT alanazijowaher drugrepurposinganewhopeindrugdiscoveryforprostatecancer
AT saidalmermeshmohammadhajaj drugrepurposinganewhopeindrugdiscoveryforprostatecancer
AT anwarsirajudheen drugrepurposinganewhopeindrugdiscoveryforprostatecancer